Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

There are a total of 93 products in Phase I-III development for PD treatment. The Parkinson’s disease (PD) therapeutic ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

GOTHENBURG, SWEDEN / ACCESSWIRE / November 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November ...

Researchers Develop Analytical Pipeline to Identify Unexploited ... activity could provide continual and improved treatment for the symptoms of Parkinson's disease (PD) ... What the Trained ...

Researchers Develop Analytical Pipeline to Identify Unexploited ... In the future, the discovery may be used in treatment for Parkinson's ...

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...

It had an excellent phase 1b dataset with a very strong treatment effect on the primary ... leading on-market brands in ...

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational ... clinical trial evaluating prasinezumab for ...